Karyopharm Therapeutics (KPTI) Receivables - Net (2019 - 2026)

Karyopharm Therapeutics (KPTI) has reported Receivables - Net for 8 consecutive years, with $29.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Receivables - Net fell 9.29% year-over-year to $29.9 million; the trailing twelve-month figure through Jun 2026 stood at $29.9 million (down 9.29% YoY), and the FY2025 full-year result was $26.2 million, down 14.91% from the prior year.
• Receivables - Net advanced to $29.9 million in Q2 2026 per KPTI's latest filing, from $26.2 million in the prior quarter.
• Across five years, Receivables - Net topped out at $47.1 million in Q4 2022 and bottomed at $23.5 million in Q2 2022.
• Historically, Receivables - Net has averaged $31.9 million across 5 years, with a median of $31.8 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Receivables - Net soared 109.3% in 2022, then plunged 42.74% in 2023.
• Over 5 years, Receivables - Net stood at $47.1 million in 2022, then slumped by 42.74% to $27.0 million in 2023, then grew by 14.11% to $30.8 million in 2024, then decreased by 14.91% to $26.2 million in 2025, then climbed by 14.11% to $29.9 million in 2026.
• According to Business Quant data, Receivables - Net over the past three periods registered $29.9 million, $26.2 million, and $31.9 million for Q2 2026, Q4 2025, and Q3 2025 respectively.